XOMA vs TBPH โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
TBPH Captures Institutional Edge (3โ1 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Theravance Biopharma, Inc. (TBPH) driven by superior Valuation, Growth & Margin, Options & Structure while XOMA counters with relative strength in Momentum & Technical. Fundamentally, XOMA trades at 21.5x Forward P/E with -3.9% operating margin (-22.6% YoY revenue) versus TBPH at 13.4x Forward P/E and 8.9% operating margin (-20.9% YoY). In options structure, XOMA sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against TBPH sits in UNCLASSIFIED (16th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | XOMA | TBPH | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $781.8M | $884.2M | Larger Scale | TBPH |
| Trailing P/E Ratio Valuation | 28.2x | 16.4x | Lower Multiple | TBPH |
| Forward P/E Ratio Valuation | 21.5x | 13.4x | Lower Multiple | TBPH |
| Revenue Growth (YoY) Growth | -22.6% | -20.9% | Higher Growth | TBPH |
| Operating Margin (TTM) Profitability | -3.9% | 8.9% | Higher Margin | TBPH |
| Net Profit Margin Profitability | 69.6% | 51.6% | Higher Margin | XOMA |
| Return on Equity (ROE) Capital Efficiency | 34.2% | 20.9% | Higher ROE | XOMA |
| 52-Week Range Position Momentum | 78% ($22โ$45) | 50% ($13โ$21) | Stronger Trend | XOMA |
| Beta / 30D Volatility Risk Regime | 0.68ฮฒ ยท 37% Vol | 0.48ฮฒ ยท 2% Vol | Lower Realized Risk | TBPH |
| Unified Institutional Score Composite Signal | 55.8 / 100 (HOLD) | 54.9 / 100 (HOLD) | Higher Composite | XOMA |